Literature DB >> 8725888

Histopathological effects of androgen deprivation in prostatic cancer.

F Civantos1, M S Soloway, J E Pinto.   

Abstract

Thanks to earlier detection of clinically significant prostatic adenocarcinoma by measurement of serum prostate-specific antigen (PSA) levels, increasing numbers of patients are undergoing radical prostatectomy. However, the curative potential of this procedure is seriously limited by clinical understaging, which results in positive surgical margins and a marked increase in disease progression. In a multicenter study, histopathologic evaluation of radical prostatectomy specimens showed that presurgical androgen deprivation with leuprolide plus flutamide reduced the incidence of surgical margin involvement by 62%. In patients who received androgen deprivation therapy, characteristic and recognizable histopathologic changes in nontumor glands included atrophy, basal cell prominence, vacuolated luminal cell layers, and squamous and transitional cell metaplasia. Androgen deprivation markedly reduced the incidence of prostatic intraepithelial neoplasia (PIN) to 35%. The effects of androgen deprivation on prostatic carcinoma included smaller tumor glands, pyknosis and empty glandular spaces, and vacuolization and degeneration of tumor cells with an inflammatory response. Similar but less pronounced changes with no decrease in PIN were observed in finasteride-treated patients. It is important for pathologists to be aware of these histological changes and process tissue appropriately, because the changes affect the recognition and histological grading of tumors in radical prostatectomy specimens.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725888

Source DB:  PubMed          Journal:  Semin Urol Oncol        ISSN: 1081-0943


  13 in total

Review 1.  Prostate cancer prevention: review of target populations, pathological biomarkers, and chemopreventive agents.

Authors:  R Montironi; R Mazzucchelli; J R Marshall; P H Bartels
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

Review 2.  [Chemoprevention of prostate cancer].

Authors:  B Djavan; I Thompson; M S Michel; M Waldert; C Seitz
Journal:  Urologe A       Date:  2004-05       Impact factor: 0.639

3.  Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer.

Authors:  Douglas G McNeel; Heath A Smith; Jens C Eickhoff; Joshua M Lang; Mary Jane Staab; George Wilding; Glenn Liu
Journal:  Cancer Immunol Immunother       Date:  2011-12-31       Impact factor: 6.968

Review 4.  Pathological changes in prostate lesions after androgen manipulation.

Authors:  R Montironi; C C Schulman
Journal:  J Clin Pathol       Date:  1998-01       Impact factor: 3.411

5.  Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens.

Authors:  E David Crawford; Kyle O Rove; Al B Barqawi; Paul D Maroni; Priya N Werahera; Craig A Baer; Hari K Koul; Cory A Rove; M Scott Lucia; Francisco G La Rosa
Journal:  Prostate       Date:  2012-11-20       Impact factor: 4.104

6.  Therapeutic strategies for localized prostate cancer.

Authors:  J H Lynch; J T Batuello; E D Crawford; L G Gomella; J Kaufman; D P Petrylak; A B Joel
Journal:  Rev Urol       Date:  2001

Review 7.  Should finasteride be used to prevent prostate cancer?

Authors:  Neil Fleshner; Girish Kulkarni
Journal:  Curr Treat Options Oncol       Date:  2006-09

8.  Bipolar versus monopolar technique for palliative transurethral prostate resection.

Authors:  Dirk P J Michielsen; Danny Coomans; Benedikt Engels; Johan G Braeckman
Journal:  Arch Med Sci       Date:  2010-10-26       Impact factor: 3.318

9.  [Drug treatment of alopecia].

Authors:  H Wolff
Journal:  Internist (Berl)       Date:  2015-10       Impact factor: 0.743

10.  Low grade urothelial carcinoma mimicking basal cell hyperplasia and transitional metaplasia in needle prostate biopsy.

Authors:  Julian Arista-Nasr; Braulio Martinez-Benitez; Leticia Bornstein-Quevedo; Elizmara Aguilar-Ayala; Claudia Natalia Aleman-Sanchez; Raul Ortiz-Bautista
Journal:  Int Braz J Urol       Date:  2016 Mar-Apr       Impact factor: 1.541

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.